Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer

Conclusions: Compared with TMT, RC is associated with a significant reduction in ACM and BCSM. However, the risks and survival benefits of RC should be weighed, especially in older patients, and our results further suggest that there may be no difference in the prognosis of RC and TMT in patients ≥80 years of age. These results are preliminary and emphasize the need for randomized controlled trials to compare TMT and RC.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research